TREA

97909703 - TIDES WUXI TIDES

Follow

Information

  • Trademark
  • 97909703
  • Serial Number
    97909703
  • Filing Date
    April 27, 2023
    a year ago
  • Transaction Date
    January 28, 2025
    a month ago
  • Status Date
    April 30, 2024
    10 months ago
  • Published for Opposition Date
    March 05, 2024
    a year ago
  • Location Date
    April 30, 2024
    10 months ago
  • Status Code
    688
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    KETCHUM, BRENDAN
  • Attorney Docket Number
    USTF10168855
    Attorney Name
    Jonathan M. Rixen
    Law Office Assigned Location Code
    N70
  • Owners
Information
Mark Drawing Code
3
Mark Identification
TIDES WUXI TIDES
Case File Statements
  • GS0401: Metal treating; Material treatment information; Processing and handling of chemical reagents, namely, treatment of materials in the nature of chemicals; Cloth treating; Paper treating; Processing of oil; Stripping finishes, namely, treatment of wood for preservation purposes; Recycling of waste and trash; Air purification; Processing of medicinal materials being material treatment services in connection with recycling; Cryopreservation services; Providing information relating to material treatment; Custom assembling of materials for others being custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, and vaccines by pharmaceutical compounders; Processing of biomedical materials for others being biomanufacturing for others in the nature of manufacturing of pharmaceuticals and vaccines using biological organisms in the manufacturing process; Customized production service being custom manufacturing of pharmaceuticals; Custom manufacture of pharmaceuticals medical preparation
  • GS0051: Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Raw material medicine, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Pharmaceutical preparations, for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; pharmaceutical preparations, namely, antivirals; Chemico-pharmaceutical preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases; Biological preparations for medical purposes for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases; Chemical preparations for the diagnosis of pregnancy; Chemical preparations for pharmaceutical or medical purposes, for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Chemical preparations for medical purposes, namely, chemical reagents for medical purposes; Chemical preparations for medical purposes; Diagnostic preparations for medical purposes; Nutritional supplements; Drugs for medical purposes; Reagent paper for medical purposes; Medical reagents; Disinfectants for hygiene purposes; Cultures of microorganisms for medical use; Biomedicine; Adjuvants for medical purposes; Vaccines; Veterinary preparations
  • CC0000: Color is not claimed as a feature of the mark.
  • DS0000: "WUXI"
  • GS0421: Computer programming; Material testing; Technical research in the field of pharmaceutical studies; Research and development of new products for others; Technology consultancy in the field of cybersecurity; Chemical analysis; Chemistry services, namely, chemistry consultation; Chemical research; Biological research; conducting clinical trials for others, being for scientific and medical research; Quality checking and testing, namely, quality control for others; Scientific laboratory services; Genome structure and function analysis; Gene screening, namely, DNA screening for scientific research purpose; Biomedical research services; Stem cell research service; Drug research and development services, namely, pharmaceutical research; cell culture services for scientific research purposes, for others; Design and development of computer hardware and software; Development and creation of computer programs for data processing; Computer programming in the field of medical treatment; Product quality testing; assessment of quality of products; Scientific research; Surveying; Bacteriological research; The design, production in the nature of design, or maintenance of a computer program; Computer software design; Computer technology consultancy in the field of engineering; Information technology consulting relating to computer network design; Artificial intelligence technology consulting; Research on artificial intelligence technology; Research and development of new products; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Drug evaluation, namely, pharmaceutical product evaluation; Vaccine research and development services; Cancer medicine research; Biotechnology research; Drug testing being testing of pharmaceuticals; Pharmaceutical research; Cancer scientific research for medical purposes; Development and Testing of Chemical production methods; Implementation of early evaluation in the field of new drugs, namely, product quality testing; Biochemical research and analysis; Chemical analysis evaluation service; Chemical synthesis evaluation service; scientific research of the mode of action of chemical combinations on animals
Case File Event Statements
  • 11/7/2023 - a year ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 5/1/2023 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 5/25/2023 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 5/26/2023 - a year ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 10/28/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/7/2023 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/7/2023 - a year ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 1/5/2024 - a year ago
    8 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 1/5/2024 - a year ago
    9 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 1/5/2024 - a year ago
    10 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 1/5/2024 - a year ago
    11 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 1/5/2024 - a year ago
    12 - TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED Type: EWOR
  • 1/5/2024 - a year ago
    13 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 1/5/2024 - a year ago
    14 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 1/8/2024 - a year ago
    15 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/8/2024 - a year ago
    16 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/9/2024 - a year ago
    17 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/26/2024 - a year ago
    18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/14/2024 - a year ago
    19 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/14/2024 - a year ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 3/5/2024 - a year ago
    21 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 3/5/2024 - a year ago
    22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 7/4/2024 - 8 months ago
    24 - TEAS STATEMENT OF USE RECEIVED Type: EISU
  • 1/22/2025 - a month ago
    27 - TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED Type: EWOR
  • 1/22/2025 - a month ago
    29 - TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Type: EWAF
  • 1/22/2025 - a month ago
    26 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 1/22/2025 - a month ago
    28 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 1/22/2025 - a month ago
    25 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 4/30/2024 - 10 months ago
    23 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM